Table 2.
The association of NLRP3 rs35829419 with the risk for macro- and microvascular complications in type 2 diabetes patients.
| T2D complications | All patients | Male patients | ||||||
|---|---|---|---|---|---|---|---|---|
| CC N (%) |
CA + AA N (%) |
OR (95% CI) | P | CC N (%) |
CA + AA N (%) |
OR (95% CI) | P | |
| Macrovascular | 35 (21.9) | 11 (52.4) | 3.93 (1.54–10.00) | 0.004 | 21 (23.1) | 8 (57.1) | 4.44 (1.39–14.25) | 0.012 |
| PAOD | 7 (4.4) | 3 (14.3) | 3.64 (0.86–15.34) | 0.078 | 4 (4.4) | 3 (21.4) | 5.93 (1.17–30.06) | 0.032 |
| ICD | 12 (7.5) | 4 (19.1) | 2.90 (0.84–10.01) | 0.092 | 9 (9.9) | 3 (21.4) | 2.48 (0.58–10.60) | 0.219 |
| MI | 25 (15.6) | 7 (33.3) | 2.70 (0.99–7.36) | 0.052 | 14 (15.4) | 5 (35.7) | 3.06 (0.89–10.48) | 0.076 |
| Microvascular | 28 (17.5) | 6 (28.6) | 1.89 (0.67–5.29) | 0.228 | 17 (18.7) | 6 (42.9) | 3.26 (1.00–10.65) | 0.050 |
| End-stage kidney failure | 20 (12.5) | 5 (23.8) | 2.19 (0.72–6.63) | 0.166 | 11 (12.1) | 5 (35.7) | 4.04 (1.14–14.27) | 0.030 |
| Retinopathy | 12 (7.5) | 3 (14.3) | 2.06 (0.53–7.98) | 0.298 | 9 (9.9) | 1 (7.1) | 0.70 (0.08–6.00) | 0.746 |
| Neuropathy | 12 (7.5) | 1 (4.8) | 0.61 (0.08–4.97) | 0.646 | 8 (8.8) | 3 (21.4) | 2.83 (0.65–12.29) | 0.165 |
PAOD: peripheral arterial occlusive disease; 16 (8.85%) ICD: ischemic cerebrovascular disease; MI: myocardial infarction.